Is it possible for FDA regulatory scientists and industry scientists to work together?

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 3, 2012, Pages 390-392

  Woosley, R L ^a,b  

^a CRITICAL PATH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; CONSENSUS; DRUG INDUSTRY; EDUCATION PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; PRIORITY JOURNAL; PRODUCTIVITY; PUBLIC HEALTH; SCIENTIST; TEAMWORK;

COOPERATIVE BEHAVIOR; DRUG INDUSTRY; HEALTH PERSONNEL; HUMANS; PUBLIC HEALTH; SCIENCE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84857205702     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.304     Document Type: Conference Paper

References (10)

1. Wikipedia. Institute for Food Safety and Health 〈http://en. wikipedia.org/wiki/Institute-for-Food-Safety-and-Health〉 (2011).
2. US Food and Drug Administration. Innovation or stagnation: challenges and opportunity on the critical path to new medical products 〈http://www.fda. gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/ CriticalPathOpportunitiesReports/ucm077262. htm〉 (March 2004).
3. Prinz, F., Schlange, T. & Asadullah, K. Believe it or not: how much can we rely on published data on potential drug targets? Nat. Rev. Drug Discov.10, 712 (2011).
4. US Food and Drug Administration. Guidance for industry: qualification process for drug development tools (draft guidance) 〈http://www.fda.gov/ downloads/Drugs/guidancecomplianceregulatoryinformation/Guidances/UCM230597. pdf〉 (October 2010).
5. Sistare, F.D. et al. Towards consensus practices to qualify safety biomarkers for use in early drug development. Nat. Biotechnol. 28, 446-454 (2010).
6. Woosley, R.L., Myers, R.T. & Goodsaid, F. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science. Clin. Pharmacol. Ther. 87, 530-533 (2010).
7. Romero, K., Corrigan, B., Neville, J., Kopko, S. & Cantillon, M. Striving for an integrated drugdevelopment process for neurogeneration: the coalition against major diseases. Neurodegener. Dis. Manage. 1, 379-385 (2011).
8. Romero, K. et al. The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases. Clin. Pharmacol. Ther. 86, 365-367 (2009).
9. Moore, H.M., Compton, C.C., Lim, M.D., Vaught, J., Christiansen, K.N. & Alper, J. Biospecimen research network symposium: advancing cancer research through biospecimen science. Cancer Res. 69, 6770-6772 (2009).
10. Mattsson, N., Blennow, K. & Zetterberg, H. Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. Clin. Chem. Lab. Med. 48, 603-607 (2010).